[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521916":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":120,"collaborators":122,"id":126,"slug":127,"hasResults":128,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":36,"eligibilityCriteria":132,"healthyVolunteers":128,"sex":133,"minAge":134,"maxAge":36,"enrollmentInfo":135,"targetDuration":36,"studyType":138,"phases":139,"briefSummary":141,"conditions":142,"keywords":146,"overallStatus":44,"whyStopped":36,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},{"fullName":5,"class":6},"MBQ Pharma","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MBQ-167 oral capsule","EXPERIMENTAL","A dose ranging from 10mg to 400mg BID following a standard 3+3 cohort design",[13],"Drug: MBQ-167",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","MBQ-167","MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42",[9],[21,22,23,24,25],"Rac and Cdc42 inhibitor","Rac inhibitor","Cdc42 inhibitor","PAK inhibitor","Rac\u002FCdc42 inhibitor",[27],{"name":28,"affiliation":29,"role":30},"Neil Sankar, MD","CMO, MBQ Pharma","STUDY_DIRECTOR",[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Scott Houston","CONTACT","(415) 404 8838",null,"scott.houston@mbqpharma.com",{"name":39,"role":34,"phone":36,"phoneExt":36,"email":40},"Jose Rodriguez-Orengo, PhD","jose.rodriguez@mbqpharma.com",[42,67,83,100],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Precision Next Gen Oncology & Research Center","RECRUITING","Beverly Hills","California","90212","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-118.40036,34.07362,{"lat":54,"lon":53},[57,61,64],{"name":58,"role":34,"phone":59,"phoneExt":36,"email":60},"Rebecca Godin","424-777-0708","RebeccaG@NextGenOnc.com",{"name":62,"role":34,"phone":59,"phoneExt":36,"email":63},"Francisco Capilla","FranciscoC@NextGenOnc.com",{"name":65,"role":66,"phone":36,"phoneExt":36,"email":36},"Kumar Sankhala, MD","PRINCIPAL_INVESTIGATOR",{"facility":68,"status":44,"city":69,"state":70,"zip":71,"country":48,"countryCode":49,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Florida Cancer Specialists \u002F Sarah Cannon Research Institute \u002F SCRI","Sarasota","Florida","34232",{"type":51,"coordinates":73},[74,75],-82.53065,27.33643,{"lat":75,"lon":74},[78,82],{"name":79,"role":34,"phone":80,"phoneExt":36,"email":81},"Judy S Wang, MD","941-377-9993","jswang@flcancer.com",{"name":79,"role":66,"phone":36,"phoneExt":36,"email":36},{"facility":84,"status":44,"city":85,"state":86,"zip":87,"country":48,"countryCode":49,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Sarah Cannon Research Institute\u002FSCRI","Nashville","Tennessee","37203",{"type":51,"coordinates":89},[90,91],-86.78444,36.16589,{"lat":91,"lon":90},[94,98],{"name":95,"role":34,"phone":96,"phoneExt":36,"email":97},"Melissa Sindler","844-482-4812","scri.ddureferrals@scri.com",{"name":99,"role":66,"phone":36,"phoneExt":36,"email":36},"Denise Yardley, MD",{"facility":101,"status":44,"city":102,"state":36,"zip":103,"country":104,"countryCode":105,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"FDI Clinical Research","San Juan","00927","Puerto Rico","PR",{"type":51,"coordinates":107},[108,109],-66.10572,18.46633,{"lat":109,"lon":108},[112,116,119],{"name":113,"role":34,"phone":114,"phoneExt":36,"email":115},"Mirelis Acosta-Rivera, MD","(787) 722-1248","info@fdipr.com",{"name":117,"role":34,"phone":114,"phoneExt":36,"email":118},"Michelle Echeandia, MT, MSMT","mecheandia@fdipr.com",{"name":113,"role":66,"phone":36,"phoneExt":36,"email":36},{"type":121,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR",[123],{"name":124,"class":125},"Congressionally Directed Medical Research Programs","FED","100521916","phase-1-a-study-of-oral-mbq-167-in-participants-with-advanced-breast-cancer-100521916",false,"NCT06075810","A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer","A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer","Key Inclusion Criteria:\n\n* The investigator will evaluate these and other criteria to determine whether a participant can be included in this study.\n* Histologically and\u002For cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available.\n* Participants with known brain metastases may be eligible if specific conditions are met.\n* Life expectancy ≥6 months, in the opinion of the investigator, after starting MBQ-167.\n* Are able to swallow capsules twice daily with a meal.\n\nKey Exclusion Criteria:\n\n* The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study.\n* Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167.\n* Females who are pregnant or breastfeeding.\n* Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.\n* Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.\n* Active malignancies other than advanced breast cancer will be excluded from the study.","ALL","21 Years",{"count":136,"type":137},48,"ESTIMATED","INTERVENTIONAL",[140],"PHASE1","A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.",[143,144,145],"Breast Cancer","Breast Neoplasm","Breast Cancer Stage IV",[147,148,149],"Advanced Breast Cancer","Metastatic Breast Cancer","Recurrent Breast Cancer","2024-12-09",{"date":152,"type":153},"2024-12-12","ACTUAL",{"date":155,"type":153},"2023-11-09",{"date":157,"type":137},"2025-10-31",{"name":5,"class":6},4]